# Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

> **NCT03624010** · PHASE2 · COMPLETED · sponsor: **Tenax Therapeutics, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Hypertension Pulmonary Secondary Heart Failure
- Right Sided Heart Failure With Normal Ejection Fraction
- Heart Failure With Normal Ejection Fraction

## Interventions

- **DRUG:** Levosimendan

## Key facts

- **NCT ID:** NCT03624010
- **Lead sponsor:** Tenax Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2023-04-25
- **Final completion:** 2023-04-25
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624010, "Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03624010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*